αAzithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls. by Krempaska, Kristina et al.
RESEARCH Open Access
αAzithromycin has enhanced effects on
lung fibroblasts from idiopathic pulmonary
fibrosis (IPF) patients compared to controls
Kristina Krempaska1,2,3, Sandra Barnowski1,2, Jacopo Gavini4, Nina Hobi5,6, Simone Ebener1,2, Cedric Simillion2,7,
Andrea Stokes1,2, Ronja Schliep8, Lars Knudsen8,9, Thomas K. Geiser1,2 and Manuela Funke-Chambour1,2*
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic fatal lung disease without a cure and new drug
strategies are urgently needed. Differences in behavior between diseased and healthy cells are well known and
drug response can be different between cells isolated from IPF patients and controls. The macrolide Azithromycin
(AZT) has anti-inflammatory and immunomodulatory properties. Recently anti-fibrotic effects have been described.
However, the anti-fibrotic effects on primary IPF-fibroblasts (FB) directly compared to control-FB are unknown. We
hypothesized that IPF-FB react differently to AZT in terms of anti-fibrotic effects.
Methods: Primary normal human lung and IPF-FB were exposed to TGF-β (5 ng/ml), Azithromycin (50 μM) alone or
in combination prior to gene expression analysis. Pro-collagen Iα1 secretion was assessed by ELISA and protein
expression by western blot (αSMA, Fibronectin, ATP6V1B2, LC3 AB (II/I), p62, Bcl-xL). Microarray analysis was
performed to screen involved genes and pathways after Azithromycin treatment in control-FB. Apoptosis and
intraluminal lysosomal pH were analyzed by flow cytometry.
Results: AZT significantly reduced collagen secretion in TGF-β treated IPF-FB compared to TGF-β treatment alone,
but not in control-FB. Pro-fibrotic gene expression was similarly reduced after AZT treatment in IPF and control-FB.
P62 and LC3II/I western blot revealed impaired autophagic flux after AZT in both control and IPF-FB with significant
increase of LC3II/I after AZT in control and IPF-FB, indicating enhanced autophagy inhibition. Early apoptosis was
significantly higher in TGF-β treated IPF-FB compared to controls after AZT. Microarray analysis of control-FB treated
with AZT revealed impaired lysosomal pathways. The ATPase and lysosomal pH regulator ATP6V0D2 was significantly
less increased after additional AZT in IPF-FB compared to controls. Lysosomal function was impaired in both IPF and
control FB, but pH was significantly more increased in TGF-β treated IPF-FB.
Conclusion: We report different treatment responses after AZT with enhanced anti-fibrotic and pro-apoptotic effects in
IPF compared to control-FB. Possibly impaired lysosomal function contributes towards these effects. In summary,
different baseline cell phenotype and behavior of IPF and control cells contribute to enhanced anti-fibrotic and pro-
apoptotic effects in IPF-FB after AZT treatment and strengthen its role as a new potential anti-fibrotic compound, that
should further be evaluated in clinical studies.
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Background
Idiopathic pulmonary fibrosis (IPF) is a devastating pro-
gressive lung disease causing dyspnea and cough, which
ultimately leads to respiratory failure [1]. IPF affects
mainly male patients over 60 years and genetic associa-
tions have been described [2]. The mortality is compar-
able to severe cancer disease with a median survival of
2–3 years [2]. New drugs slow down disease progression
and may prolong survival [3, 4]. Nevertheless, today no
cure is available and in advanced disease eligible patients
ultimately require lung transplantation, or else they suc-
cumb to their disease [2]. New and improved drug strat-
egies are thus urgently needed.
To develop or apply existing drugs for new use, the
underlying pathomechanisms need to be fully understood.
The pathogenesis of IPF remains still unclear. Presently it
is believed that injury of the alveolar epithelial lining
followed by aberrant wound healing is the initiating event
for IPF development [5]. Although epithelial cells are
thought to initiate fibrosis, differentiated fibroblasts, so-
called myofibroblasts, are the main mesenchymal actor
cells in fibrogenesis. They originate from local fibroblasts
or other precursor cells and produce extracellular matrix
leading to increased lung stiffness and loss of respiratory
function [6]. The differentiation into myofibroblasts is
driven by pro-fibrotic mediators, including cytokines such
as transforming growth factor-β (TGF-β) [7], which is
considered the main pro-fibrotic cytokine [8].
Fibroblasts isolated from IPF patients show particular
properties such as insufficient autophagy [9, 10]. Impaired
autophagy in IPF lungs may contribute to fibrogenesis and
promote fibroblast activation and extracellular matrix pro-
duction [11]. Autophagy can be modulated by drugs. Re-
cently, a study has shown that autophagy is reduced after
Azithromycin (AZT) treatment and affects fibrosis [12].
Autophagy inhibition in lung fibroblasts induced protea-
somal degradation of pro-fibrotic NOX4 [13]. NOX4 re-
duction then decreased myofibroblast differentiation in
normal human lung fibroblasts [12]. In vivo, AZT has
anti-fibrotic effects in the bleomycin rodent model for
lung fibrosis [14]. In clinical routine AZT is used as an
antibiotic. AZT is a potent macrolide antibiotic known to
inhibit bacterial protein synthesis by binding to the 50S
large ribosomal unit [15]. AZT shares the same mechan-
ism of antibacterial action as other macrolides, but it has
been found to accumulate more effectively in phagocytes
where it can efficiently be delivered to the site of infection
[15, 16]. AZT was also described to accumulate in other
cell types such as epithelial cells and fibroblasts [15].
Long-term use of AZT in COPD, asthma and cystic
fibrosis has been reported with improved clinical out-
comes such as reduced exacerbations and cough [17–19].
The exact mechanisms remain unknown, but anti-
inflammatory effects on macrophages and neutrophils
might be involved [20]. Inflammation also contributes to
acute exacerbations in IPF [21]. In recent retrospective
clinical observations, AZT reduced mortality in acute
exacerbations and hospitalization rates of IPF patients
[22, 23]. In addition to antimicrobial effects, AZT
might act on inflammation and thus reduce severity
of acute exacerbation. Despite recent findings of a
positive role of AZT in lung fibrosis, the role and
precise mechanism of its effects on exacerbation and
lung fibrosis remain unclear. Also, cells might act dif-
ferently when derived from patients or healthy con-
trols [24].
In our study, we tested the anti-fibrotic properties of
AZT. We hypothesized that IPF fibroblasts react differ-
ently to AZT treatment than normal fibroblasts. We
thus investigated whether AZT has enhanced anti-
fibrotic effects on IPF fibroblasts compared to control fi-
broblasts. We further investigated the underlying mecha-
nisms of divergent responses from control and IPF
fibroblasts specifically for cell death, autophagy as well
as lysosomal function.
Methods
Primary fibroblasts from IPF patients and controls
We obtained control fibroblasts from healthy lung tissue
from patients undergoing tumor resection at the Univer-
sity Hospital of Bern, Switzerland. All study participants
provided their informed written consent, as approved by
the local Ethics Committee, Bern, Switzerland (KEK-BE:
042/2015). We received additional lung fibroblasts from
control and IPF patients from diagnostic biopsies and/or
lung explants isolated and cultured as previously de-
scribed and kindly provided by Prof. Crestani, Paris,
France [25].
Material, cell culture and antibodies
We used Ham’s F-12 K (Gibco, Waltham, MA) media
supplemented with 10% Fetal Bovine Serum (FBS)
(Gibco, Waltham, MA) and 1% Penicillin Streptomycin
(Gibco, Waltham, MA) for cell culture. We treated cells
for 24 h as follows: 1. Starvation media control including
the respective vehicle control (Media without FBS plus
50 μM Ethanol as the dissolvent for AZT), 2. Azithromy-
cin (50 μM, dissolved in Ethanol) (Sigma-Aldrich, St.
Louis, MO) 3. TGF-β (5 ng/ml plus 50 μM Ethanol)
(R&D Systems, Minneapolis, MN) or 4. Azithromycin
(50 μM, dissolved in Ethanol) with simultaneous TGF-β
stimulation. Each condition was tested and repeated in
three independently performed experiments. The follow-
ing antibodies were used for immunofluorescent stain-
ing: primary monoclonal antibody mouse anti-αSMA
(Sigma-Aldrich, St. Louis, MO), monoclonal anti-
vinculin-FITC (Sigma-Aldrich, St. Louis, MO) and sec-
ondary antibody Alexa Fluor 488 goat anti-rabbit (Life
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Technologies, Carlsbad, CA). Lysotracker Green DND-26
(Life Technologies, Carlsbad, CA) dye for life lysosomal
staining. Following western blot antibodies were used:
mouse anti-αSMA (Sigma-Aldrich, St. Louis, MO), rabbit
anti-Fibronectin (FN) (Abcam, Cambridge, UK), rabbit
anti-ATP6V1B2, rabbit anti-LC3 AB (II/I), monoclonal
Smad3 and pSmad3 rabbit antibodies (Cell Signaling
Technology, Danvers, MA), rabbit anti-p62 (Sigma-Al-
drich, St. Louis, MO) and rabbit anti-Bcl-xL antibodies
(Cell Signaling Technology, Danvers, MA). Infrared IRDye
(680 or 800 CW) secondary antibodies (LI-COR Biosci-
ences, Lincoln, NE).
Isolation of primary control human lung fibroblasts
We isolated fibroblasts from human lung tissue, as de-
scribed previously [26]. Cell culture passages between 3
and 8 were used for experiments. We treated our sam-
ples for 1 h, 24 h or 48 h as described.
Isolation of total RNA and RT-qPCR
We used Nucleospin RNA kit (Macherey-Nagel,
Switzerland) to isolate RNA according to the manufac-
turer’s instructions. We used the ΔΔCt method to calcu-
late mRNA expression levels. RNA copy numbers were
normalized to β2microglobulin (β2m) expression as pre-
viously described [26]. Human forward and reverse
primers are listed in Table 1. Each condition was re-
peated three times and in independently performed
experiments.
Immunofluorescent staining and microscopy
We seeded control and IPF fibroblasts on IBIDI® cham-
ber slides (Thermo Fischer Scientific, Waltham, MA).
The cells were grown until 80% confluency was reached
and kept in resting media for 24 h. Afterwards, the cells
were fixated and incubated with the respective primary
and secondary antibodies. To identify lysosomes, we
used Lysotracker® Green dye (Life Technologies, Carlsbad,
CA) life staining. Pictures were taken with Leica DMI4000
B fluorescence microscope using the 20x and 63x magnifi-
cation (Plan-Apochromat 63x/0.7 Oil).
Western blot
We treated control and IPF fibroblasts with TGF-β (5
ng/ml) and/or AZT (50 μM) for 48 h for the analysis of
αSMA, Fibronectin, ATP6V1B2, LC3 AB (II/I) and p62.
Incubation time for Bcl-xL analysis was 24 h and 1 h to
evaluate SMAD3 phosphorylation. Cells were harvested
using Pierce IP Lysis Buffer® (Thermo Fischer Scientific,
Waltham, MA) according to the manufacturer’s instruc-
tions. We normalized infrared fluorescent signals to in-
ternal control monoclonal β-actin mouse antibody (LI-
COR Biosciences, Lincoln, NE) and quantified their in-
tensities as previously described [26].
Apoptosis and cell death measurements
Fibroblasts were grown to 80% confluency on 6-well
plates preceding treatment. We used Annexin V (A) and
Propidium Iodide (PI) (Biolegend, San Diego, CA) dyes
according to manufacturer’s instructions for flow cytom-
etry analysis. To evaluate cytotoxicity of Azithromycin in
control and IPF fibroblasts, we measured the release of
lactate dehydrogenase (LDH) in cell supernatants after
24 h of treatment by a colorimetric assay according to
the manufacturer’s instructions. We measured the op-
tical densitiy at 540 nm using an Infinite M1000 PRO
microplate reader (TECAN, Männerdorf, Switzerland) as
previously described [27]. Bcl-xL was measured by west-
ern blot as described above.
Lysosomal pH measurements
We determined lysosomal pH using FITC-Dextran
loaded fibroblasts following a previously published
protocol [28]. We seeded control and IPF fibroblasts in
6-well plates with a FITC-Dextran loaded medium solu-
tion (0.1 mg/ml – FD40S – Sigma-Aldrich) for 48 to 72
Table 1 Primer sequences for RT-qPCR
Gene of interest Forward primer Reverse primer
β2microglobulin (β2M) CTCCGTGGCCTTAGCTGTG TTTGGAGTACGCTGGATAGCCT
α-smooth muscle actin (αSMA) CAGGGCTGTTTTCCCATCCAT GCCATGTTCTATCGGGTACTTC
Collagen 1A1 (COL) CCAGAAGAACTGGTACATCAGCA CGCCATACTCGAACTGGGAAT
Fibronectin (FN) TAAAGGACTGGCATTCACTGA GTGCAAGGCAACCACACTGAC
ATP6V1B2 TAGTTCAGGTATTTGAAGGGAC GGTGTTCGGAGAATATCCC
ATP6V0D2 TCTCACCTATATGACGTGCAGT GGTGGCACTTCCCCAGAATTT
RAB7B GGCCAGCATCCTCTCCAAGATTATC GATGCAGCCATCGGAGCCCTTGT
TMEM55b GGTTATCTGTGGACATTGCA ATAGATGACACTTTCCTGCAG
Cathepsin B (CTSB) TTCTTGCGACTCTTGGGACTTC TGACGAGGATGACAGGGAACTA
Cathepsin C (CTSC) CCTATCTTGACCTGCTGGG CTTGTGGTCCCATAACCGA
Cathepsin D (CTSD) AACTGCTGGACATCGCTTGCT CATTCTTCACGTAGGTGCTGGA
Krempaska et al. Respiratory Research           (2020) 21:25 Page 3 of 16
h prior to treatment. FITC-Dextran medium was then
removed by aspiration and fresh cell culture medium
was added with the respective treatments for a 24 h in-
cubation time. We determined the lysosomal pH by flow
cytometry using a standard curve scale (pH scale from 4
to 6) which was compared to the treated samples.
Elisa
We used a monoclonal ELISA kit (R&D Systems, Min-
neapolis, MN) according to the manufacturer’s instruc-
tions to determine concentrations for pro-collagen Iα1
(pro-Col1A1).
Transmission electron microscopy
AZT-induced vacuolar structures of control and IPF fi-
broblasts were analyzed in Hannover, Germany at the
Institute for Anatomy by transmission electron micros-
copy. The preparation for electron microscopic evalu-
ation was performed according to established methods
[29]. In brief, cell pellets were fixed by immersion using
a fixation mixture of 1.5% PFA, 1.5% GA in 0.15M
HEPES buffer. Afterwards, fixed cells were embedded in
epoxy resin (Epon®) and ultrathin sections of a thickness
of 60 nm were cut. Sections were investigated using a
transmission electron microscope (Morgagni, Fei, Eind-
hoven, The Netherlands).
GeneChip microarray assay and data analysis
We performed microarray analysis to screen involved
pathways after AZT treatment in control lung fibro-
blasts. Microarray analysis was performed on isolated
total RNA samples. RNA isolation is described above
and concentration was determined spectrophotometric-
ally using Nanodrop (NanoDrop 2000). Sample prepar-
ation for microarray hybridization was carried out as
described in the Affymetrix GeneChip WT PLUS Re-
agent Kit User Manual (Affymetrix, Inc., Santa Clara,
CA, USA). In brief, 100 ng (50 ng of sample no. 09) of
total RNA was used to generate double-stranded cDNA.
15 μg of subsequently synthesized cRNA was purified
and reverse transcribed into sense-strand (ss) cDNA,
whereat unnatural dUTP residues were incorporated.
Purified ss cDNA was fragmented using a combination
of uracil DNA glycosylase (UDG) and apurinic/apyrimi-
dinic endonuclease 1 (APE 1) followed by a terminal la-
beling with biotin. 3,8 μg fragmented and labeled ss
cDNA were hybridized to Affymetrix Clariom S human
arrays for 16 h at 45 °C in a GeneChip hybridization
oven 640. Hybridized arrays were washed and stained in
an Affymetrix Fluidics Station FS450, and the fluores-
cent signals were measured with an Affymetrix Gene-
Chip Scanner 3000 7G. Fluidics and scan functions were
controlled by Affymetrix GeneChip Command Console
v4.1.3 software. Sample processing was performed at an
Affymetrix Service Provider and Core Facility, “KFB -
Center of Excellence for Fluorescent Bioanalytics” (Re-
gensburg, Germany; www.kfb-regensburg.de). RNA
microarray data from control lung fibroblasts treated
with Azithromycin versus non-treated can be down-
loaded from the ArrayExpress database at EMBL-EBI
(www.ebi.ac.uk/arrayexpress) under accession number
E-MTAB-8488. Summarized probe set signals in log2
scale were calculated by using the GCCN-SST-RMA algo-
rithm with the Affymetrix GeneChip Expression Console
v1.4 Software. After exporting into Microsoft Excel, aver-
age signal values, comparison fold changes and signifi-
cance P values were calculated. Probe sets with a fold
change above 2.0 fold and a student’s T-test P value < 0.05
were considered statistically significant. Differentially
expressed genes were further analyzed and evaluated in
the Department of Biostatistics, Bern, Switzerland (Cedric
Simillion). Microarray data were analyzed using custom
CDFs and data was normalized and log-transformed using
the RMA method [30, 31]. Differential gene expression
was calculated using the limma R package [32]. Pathway
analysis was conducted with the SetRank package [33].
Statistical analysis
Comparisons between control and IPF fibroblasts under
different treatment conditions were tested by ONE-way
ANOVA followed by Bonferroni’s multiple comparison
post test for unequal sample sizes and Tukey’s post test
for equal sample sizes using GraphPad Prism 7 (Graph-
Pad Software Inc., La Jolla, CA). Student’s T-test was
used to compare the mean (± SE) between only two
treatment conditions. P < 0.05 was considered statisti-
cally significant.
Results
AZT has enhanced anti-fibrotic effects on extracellular
matrix formation, cytokine production and myofibroblast
differentiation in IPF fibroblasts compared to controls
We investigated whether Azithromycin (AZT) differently
affects the fibrotic response in lung fibroblasts from nor-
mal human lung fibroblasts and IPF fibroblasts (referred
to as controls and IPF-FB). We found that gene expres-
sion of the pro-fibrotic markers collagen Iα1 (Col1A1)
and fibronectin (FN) were expectedly increased after
TGF-β stimulation over 24 h in both cell types (Fig. 1a
and b). Additional AZT treatment significantly reduced
Col1A1 gene expression in control and in IPF fibroblasts
(Fig. 1a). The pro-fibrotic marker FN was not signifi-
cantly reduced neither in control nor in IPF fibroblasts
(Fig. 1b) when combined data from cells from different
individuals were analyzed. However, when the individual
control and IPF fibroblasts were analyzed, FN was also
significantly reduced after AZT and TGF-β treatment
(Additional file.1: Figure S1A and S1B). This statistical
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Fig. 1 (See legend on next page.)
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discrepancy was due to the high inter-individual variabil-
ity of the TGF-β treatment response we observed in pri-
mary lung fibroblasts. In control fibroblasts pro-Col1a1
protein expression was not reduced after addition of
AZT, while IPF fibroblasts showed a significant reduc-
tion compared to controls (Fig. 1c). Similar, no reduc-
tion was seen for FN protein expression in control
fibroblasts after AZT in addition to TGF-β, but FN pro-
tein expression was significantly reduced in IPF fibro-
blasts compared to controls (Fig. 1d). We speculate that
differences between gene and protein expression might
be influenced by enhanced post-transcriptional effects of
AZT in IPF fibroblasts compared to controls. Last, we
analyzed the myofibroblast differentiation marker αSMA
by qPCR, western blot and immunofluorescent staining.
AZT treatment in addition to TGF-β treatment signifi-
cantly reduced αSMA in control and IPF fibroblasts on
gene expression level (Additional file 1: Figure S1C).
Combination treatment with AZT showed a visual re-
duction of actin fibers in both control (not shown) and
IPF fibroblasts (Fig. 1e). Notably, we observed fortuit-
ously vacuolar formations after AZT treatment in most
of control (not shown) and IPF fibroblasts in immuno-
fluorescence staining for αSMA (Fig. 1e). Protein expres-
sion of αSMA was only significantly decreased in IPF
fibroblasts after additional AZT treatment (Fig. 1f). IPF
fibroblasts are considered to be more sensitive towards
TGF-β treatment [34]. With regards to αSMA protein
expression, we could observe enhanced TGF-β respon-
siveness in IPF fibroblasts compared to controls, al-
though not statistically significant in our experiment
(Fig. 1f).
Azithromycin interferes with autophagy in control and
IPF fibroblasts
Vacuolar formations in Fig. 1e suggest that AZT might
interfere with lysosomal and/or autophagic processes.
We thus performed an LC3B immunofluorescent stain-
ing as a marker for autophagosomes. As shown in Fig. 2a,
AZT induced an accumulation of LC3B positive cells in
control fibroblasts compared to AZT non-treated cells
(RM and TGF-β). We further analyzed the protein ex-
pression of the autophagic markers LC3I, LC3II and
p62. AZT treatment increased the LC3II/I ratio as a
measurement of autophagic flux with and without TGF-
β in both control and IPF fibroblasts (Fig. 2b). Increased
ratio of LC3II/I indicates decreased autophagic flux and
thus decreased autophagic activity [35]. For confirm-
ation, we performed p62 western blot analysis which
serves as a selective substrate for autophagy and is accu-
mulated upon autophagy inhibition. While increase of
p62 protein expression was not significant in control fi-
broblasts after combined AZT and TGF-β treatment,
IPF fibroblasts had a significant increase in p62 protein
expression, and thus more autophagy reduction than
controls (Fig. 2c).
Azithromycin enhanced early apoptosis in IPF fibroblasts
compared to controls
To determine AZT cytotoxicity, we measured LDH re-
lease from cell supernatants after treatment. No cytotox-
icity was observed in control fibroblasts treated with
increasing concentration of AZT (Fig. 3a). Interestingly,
we observed increased LDH levels in most but not all
IPF fibroblasts after AZT with or without TGF-β (Fig.
3b). No statistical difference could be detected due to
inter-individual variability. Our results suggest that some
IPF fibroblasts are more sensitive to AZT treatment than
control fibroblasts. To further analyze AZT-induced cell
death and apoptosis, we performed Annexin V/PI stain-
ing measured by flow cytometry. Both control and IPF
fibroblasts showed increased early apoptosis defined as
Annexin positive and PI negative signal after co-
stimulation with AZT and TGF-β compared to TGF-β
(See figure on previous page.)
Fig. 1 Anti-fibrotic effects of AZT in control and IPF fibroblasts. Isolated control human lung fibroblasts (n = 5) and IPF fibroblasts (n = 5) were
treated with resting media (RM) for 24 h, 50 μM AZT, 5 ng/ml TGF-β or co-incubated with TGF-β + AZT (T + A). Pro-fibrotic gene expression was
determined by RT-qPCR (a: Col1A1, b: FN). Data represents fold increase relative to the negative control (RM). One-way ANOVA followed by
Tukey’s post test was used for statistical analysis. Protein expression was determined by ELISA (c: pro-Col1A1) and one-way ANOVA followed by
Bonferroni’s post test was used for statistical analysis. For western blot analysis (d: FN; f: αSMA) one-way ANOVA followed by Tukey’s post was
used to analyze data. a Col1A1 gene expression was significantly reduced in control and IPF fibroblasts after AZT and TGF-β treatment compared
to TGF-β alone (**p-value ≤0.01, ***p-value ≤0.001). b FN gene expression was not significantly altered after AZT neither in control nor in IPF
fibroblasts compared to TGF-β alone. c Collagen (pro-Col1A1) production was measured by ELISA in cell culture supernatant from control (n = 4)
and IPF fibroblasts (n = 5). Additional AZT treatment induced a significant reduction in collagen secretion compared to TGF-β treatment alone in
IPF fibroblasts, but not in control fibroblasts (*p-value ≤0.05). Combined data is presented and data was normalized to β2M, and means (+/−
SEM) are presented as fold increase relative to the negative control RM. Combined data were analyzed. d FN protein expression was assessed by
western blot analysis in whole cell lysates of control and IPF fibroblasts. FN protein expression was significantly reduced after AZT and TGF-β
treatment in IPF fibroblasts when directly compared to controls (*p-value ≤0.05). Combined quantified data of control and IPF patients (n = 4)
relative to RM are shown. e Immunofluorescent staining of IPF fibroblasts visually revealed that αSMA fiber expression (red) was reduced after
AZT treatment compared to TGF-β alone and induced vacuolar formations. Magnification of 20x. Scale bar = 25 μM. f αSMA protein expression
was significantly reduced only in IPF fibroblasts after AZT and TGF-β treatment compared to TGF-β alone (***p-value ≤0.001). Combined
quantified data of control and IPF patients (n = 4) relative to RM are shown. At least three independent experiments were performed
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alone. When compared to controls, AZT and TGF-β in-
duced significantly higher early apoptotic levels in IPF fi-
broblasts (Fig. 3c). In addition, we performed Bcl-xL
western blot analysis and observed a decrease in IPF fi-
broblasts compared to controls after TGF-β and AZT
(Fig. 3d), indicating reduced anti-apoptotic activity by
Bcl-xL.
Azithromycin alters several genes involved in lysosomal
pathways
To further elucidate the involved mechanisms of AZT
effects, we performed microarray screening of control
lung fibroblasts with and without AZT treatment.
Microarray analysis showed the engagement of several
lysosomal genes that were either up- or downregulated
(Fig. 4a). A heat-map from microarray analysis with the
24 most differently regulated genes (p < =0.005) (Fig. 4a)
indicated that AZT treatment mostly impairs lysosomal
genes. RAB7B, which is among others responsible for
transportation of endosomes to the Golgi network [36]
as well as degradation of proteins in lysosomes, [37] was
downregulated after AZT treatment. Gene expression
analysis revealed a greater decrease after TGF-β and
AZT in IPF compared to controls of RAB7B if compared
Fig. 2 Azithromycin interferes with autophagy in control and IPF fibroblasts. a Immunofluorescent staining of control fibroblasts visually revealed
LC3B positive cells (green) after AZT treatment compared to TGF-β or RM alone (n = 2). Magnification of 20x. Scale bar = 25 μM. b Western blot
analysis of LC3I and LC3II was performed on control and IPF fibroblast lysates after 48 h treatment. One representative example is shown. Ratio of
LC3II/I, normalized to β-Actin, showed a significant increase after AZT alone or in combination with TGF-β in both control (white bars, n = 4) and
IPF fibroblasts (black bars, n = 4, *p-value ≤0.05, **p-value ≤0.01, ***p-value ≤0.001). c Quantification by densitometry of p62 relative to RM
showed a significant increase after AZT and TGF-β treatment in IPF fibroblasts (black bars, n = 4, *p-value ≤0.05), but not control fibroblasts. One
representative example of each western blot is shown and at least three independent experiments were performed. One-way ANOVA followed
by Tukey’s post test was used for statistical analysis
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to TGF-β stimulation alone (Fig. 4b). The lysosomal
membrane marker TMEM55b, which was upregulated in
our microarray analysis, was more increased on gene ex-
pression level after additional AZT treatment in IPF fi-
broblasts compared to controls (Fig. 4c). We further
analyzed Cathepsin B (CTSB) and found a significant in-
crease of CTSB after additional AZT treatment in con-
trol compared to IPF fibroblasts (Fig. 4d). Cathepsin C
(CTSC), a lysosomal cysteine proteinase, [38] was down-
regulated after additional AZT treatment in control and
IPF fibroblasts (Fig. 4e). Last, we analyzed gene expres-
sion of Cathepsin D (CTSD) and did not see any signifi-
cant changes after treatment (Fig. 4f).
Azithromycin induces lysosomal accumulation in control
and IPF fibroblasts
AZT-induced vacuolar structures of control and IPF fi-
broblasts were analyzed in Hannover, Germany at the
Institute for Anatomy by electron microscopy (EM). The
vacuolar structures were identified in control (Fig. 5a1–
Fig. 3 Azithromycin enhanced early apoptosis in IPF fibroblasts compared to controls. a No cytotoxicity was measured by LDH release in cell
supernatant in control fibroblasts (n = 4). b Most IPF fibroblasts (n = 5) showed increased cytotoxicity after AZT (50 μM and 500 μM) treatment in
the presence or absence of TGF-β. No statistical difference was reached. c Significant increase of early apoptosis (A+/PI-) in both control (n = 4,
***p-value ≤0.001) and IPF fibroblasts (n = 4, ****p-value ≤0.0001) is observed after co-stimulation with TGF-β and AZT. IPF fibroblasts had
significantly higher early apoptosis level after costimulation compared to controls (*p-value ≤0.05). Data represent fold increases relative to the
negative control (RM). One-way ANOVA followed by Tukey’s post test was used for statistical analysis. d Bcl-xL protein expression was assessed by
western blot analysis in whole cell lysates from control or IPF fibroblasts. Bcl-xL protein expression was significantly reduced after additional AZT
treatment in IPF fibroblasts when directly compared to controls (paired students t-test; **p-value ≤0.01). Normalized fold decrease of Bcl-xL
expression of TGF-β and AZT relative to TGF-β is shown (n = 3). At least three independent experiments were performed
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Fig. 4 (See legend on next page.)
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3) and IPF fibroblasts (Fig. 5a4–6) as late endosomes, ly-
sosomes (Fig. 5a2 and 5) or autolysosomes (Fig.5a3 and
a6). Lysosomal staining with LysoTracker (LT) green dye
confirmed EM imaging finding. Lysosomes stained by
LysoTracker green dye were clearly visible after AZT
with or without TGF-β treatment in both control and
IPF fibroblasts (Fig. 5b). Lysosomal accumulation sug-
gests that AZT might interfere with lysosomes and lyso-
somal function.
Azithromycin affects vacuolar ATPases and impairs
lysosomal pH
Microarray analysis (Fig. 4a) revealed the engagement of
various vacuolar ATPases in control fibroblasts after
AZT treatment as illustrated in Fig. 6a. Particularly
ATP6V1B2 gene expression was increased, which is a
proton pump important for lysosomal acidification and
influences its function [39]. ATP6V1B2 gene expression
was significantly upregulated after additional AZT com-
pared to TGF-β alone, but no significant difference was
observed between control and IPF fibroblasts (Fig. 6b),
neither on protein level (Additional file 1: Figure S3).
We thus analyzed additional ATPases and found that
gene expression of ATP6V0D2 was significantly less up-
regulated after additional AZT in IPF fibroblasts com-
pared to controls (Fig. 6c). Last, we analyzed ATPase
activity and function by measuring the lysosomal pH.
We observed a significant lysosomal pH increase after
additional AZT treatment in control and IPF fibroblasts
compared to TGF-β alone. However, IPF fibroblasts had
a significantly higher increase of pH and thus more im-
paired function after additional AZT when directly com-
pared to control fibroblasts (Fig. 6d and e).
Discussion
Our study shows that AZT has anti-fibrotic and pro-
apoptotic effects on primary fibroblasts and that these
effects are enhanced in IPF fibroblasts compared to con-
trol fibroblasts. We confirmed that AZT reduces gene
expression levels of pro-fibrotic genes after stimulation
with TGF-β in vitro in control as well as in IPF fibro-
blasts as recently reported [12]. In our study, AZT im-
pairs lysosomal pH and autophagy in both, IPF and
control fibroblasts but effects are enhanced in cells from
IPF patients. Our study shows for the first time that
AZT has enhanced anti-fibrotic effects on collagen, fi-
bronectin, αSMA and pro-apoptotic markers in IPF fi-
broblasts compared to controls and that impaired
lysosomal function might contribute to this finding. Our
results further support the role of AZT as a potential
treatment for IPF.
Studies with antimicrobial therapies have been previ-
ously proposed for IPF treatment as increased bacterial
burden in the BAL of IPF predicted lung functional de-
cline [40]. Preventive antibiotic treatment with Cotri-
moxazole in IPF showed decreased mortality and lower
oxygen needs [41]. However, effects of antibiotics, spe-
cifically macrolides, might go beyond the scope of its
antibiotic effects and additional effects might even indir-
ectly or directly alter disease course in IPF. Next to anti-
microbial properties, AZT is known to reduce
gastrointestinal reflux and aspiration [42]. Reflux is
thought to contribute to IPF pathogenesis [43]. The
acidic material of the reflux increases epithelial perme-
ability and as a consequence promotes fibrogenesis [43].
Moreover, direct anti-fibrotic effects of AZT have been
previously described in the bleomycin mouse model of
lung fibrosis. Wuyts et al. showed that collagen depos-
ition and spindle cell proliferation were reduced after
AZT treatment [14]. AZT has been described to highly
accumulate in tissues and fibroblasts [44] achieving up
to 100-fold higher concentrations than those in plasma
[15]. This accumulation might even amplify the anti-
fibrotic effects of AZT on fibroblasts in the fibrotic lung.
Anti-fibrotic effects have also been found with other
macrolides. A derivative of Erythromycin, EM703, was
able to reduce the transcription of collagen in normal
and scleroderma fibroblasts [45]. EM703 also downregu-
lated collagen in the bleomycin mouse model by modu-
lating TGF-β signaling in lung fibroblasts, suggesting a
potential role for macrolides in fibrosis treatment [46].
While anti-fibrotic effects have been described for
macrolides, the effects in diseased and healthy cells re-
main unexplored. Different behavior of primary diseased
cells and healthy controls is commonly observed [24]. It
has been found that IPF fibroblasts are more resistant to
(See figure on previous page.)
Fig. 4 Azithromycin alters genes involved in lysosomal pathways. a Heat map of microarray analysis in primary control lung fibroblasts (n = 5) is
shown. Presented are the 24 most differently regulated genes (p ≤0.005). Several genes are involved in lysosomal pathways. b, c: To compare
control and IPF fibroblasts, RAB7b and TMEM55b were analyzed by qPCR. b RAB7b was significantly more downregulated after additional AZT
(T + A) compared to TGF-β alone in IPF fibroblasts but not in controls (n = 4) (*p-value ≤0.05). c TMEM55b was significantly upregulated after
additional AZT (T + A) compared to TGF-β alone in IPF fibroblasts but not in controls (n = 4) (*p-value ≤0.05, ***p-value ≤0.001). d-f Cathepsin b,
c and d were analyzed by qPCR comparing control and IPF fibroblasts. d Cathepsin b was significantly higher upregulated after additional AZT in
control fibroblasts compared to IPF (*p-value ≤0.05). e Cathepsin C was significantly downregulated in control and IPF fibroblasts after additional
AZT (T + A) compared to TGF-β alone (*p-value ≤0.05). f Cathepsin D was not significantly altered after additional AZT (T + A) compared to TGF-β.
All experiments were performed in at least three independent settings. One-way ANOVA followed by Tukey’s post test was used for
statistical analysis
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collagen matrix induced cell death compared to controls
[47]. Vuga et al. found that upregulation of the WNT5A
gene was responsible for apoptosis resistance in fibro-
blasts from fibrotic lungs compared to controls [48].
Moreover, it has been shown that IPF fibroblasts have
decreased FoxO3a expression causing low autophagy
levels [49]. In IPF, decreased autophagy marker levels
are already observed at baseline [9]. Interestingly, au-
tophagy induction is considered anti-fibrotic and the au-
tophagy inducer rapamycin protects against bleomycin
induced lung fibrosis [11]. Our present findings are intri-
guing and indicate that also inhibition of autophagy by
AZT has anti-fibrotic effects [12]. TGF-β the main pro-
fibrotic marker driving lung fibrosis has been shown
to induce autophagy in lung fibroblasts [50]. These
controversial findings raise the question of which ap-
proach would be most beneficial in IPF patients: An
increase or a reduction of autophagy? Today, the role
of autophagy on fibrosis remains unclear and our
study is unable to fully answer this question. To
maintain proper cell function a balanced autophagic
flux is crucial. Autophagy is a cellular process that is
induced in both physiological as well as pathophysio-
logical conditions and it is essential for cell survival
to maintain a fine balance between protein synthesis
and degradation [51].
Fig. 5 Azithromycin induces lysosomal accumulation in control and IPF fibroblasts. a Control (A1–3) and IPF fibroblasts (A4–6) were treated with
AZT for 24 h, fixed and analyzed by electron microscopy. (A1, 4) Overview, (A2, 5) late endosomes or lysosomes (arrows), (A3, 6) autolysosomes,
double membrane (arrows). b Lysotracker green staining in control (upper images, n = 3) and IPF fibroblasts (lower images, n = 3) after 24 h
treatment with AZT in presence or absence of TGF-β confirmed the vacuolar structures as lysosomes. Magnification of 63x. Scale bar = 10 μM. All
experiments were performed in three independent experiments
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Fig. 6 (See legend on next page.)
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Autophagy inhibition is observed after AZT treatment
and prevented myofibroblast differentiation through pro-
fibrotic NOX4 suppression [12], however healthy fibro-
blasts have not been compared to IPF fibroblasts so far
and the entire mechanism of anti-fibrotic effects of AZT
is not fully understood. Our observation of intracellular
vacuolar formation and impaired lysosomal function after
AZT is in line with several published studies where AZT
induced cytoplasmic vacuoles suggested the involvement
of lysosomal function [52, 53]. Lysosomal accumulation
might occur after autophagosome clearance is blocked
and autophagosomal degradation is impaired.
Lysosomes are organelles with a low internal pH of 4.5–
5 which is known to be regulated by vacuolar ATPases
[54]. The main function is the degradation of cytoplasmic
material, including damaged organelles, proteins and
lipids [54]. Low lysosomal pH is crucial for degradation of
cytoplasmic material by lysosomal hydrolases [55]. We
show that AZT affects vacuolar ATPases and its function
is impaired. Furthermore, AZT affects several lysosomal
genes such as Rab7b. Interestingly, Rab7b was found to be
crucial for actin filament organization and remodeling.
Rab7b reduction prevented stress fiber formation, reduced
cell migration and adhesion to fibronectin [56]. We specu-
late that downregulation of the lysosomal gene Rab7b
could be one possible anti-fibrotic mechanism of AZT. In
addition, enhanced collagen degradation through lyso-
somal recycling impairment was shown in renal fibrosis
by inhibition of Cathepsin D [57]. Lysosomal impairment
with chloroquine, an endo/lysosome inhibitor had similar
effects on collagen degradation [57]. Bafilomycin is an-
other lysosomal vacuolar ATPase inhibitor which inhibits
the autophagic flux by preventing lysosomal acidification
and/or blocking the fusion of lysosomes with autophago-
somes [58, 59]. Interestingly, it has been found that Bafilo-
mycin reduced collagen and fibronectin in human atrial
myofibroblasts, but did not affect Smad2/3 phosphoryl-
ation [60]. In line with this finding, we and others also
have found that AZT did not influence SMAD phosphor-
ylation (Additional file 1: Figure S2) [12]. Although Bafilo-
mycin is a widely used autophagy inhibitor acting on the
lysosomal vacuolar ATPase in vitro, it is not approved for
therapeutical use in humans due to acute cytotoxic effects
in vivo [61]. AZT has been used for over 30 years as an
antibiotic without significant adverse health effects [15].
Although AZT represents a promising future therapeutic
option for fibrosis, antibiotic resistance should be consid-
ered as long-term use of AZT was recently shown to in-
duce macrolide resistance in severe asthma patients [62].
In addition to enhanced anti-fibrotic effects of AZT in
IPF-FB, we have observed increased apoptosis of fibro-
blasts after AZT treatment compared to control-FB. We
showed that AZT induces a stronger increase of the lyso-
somal pH in IPF-FB, which has been proposed to lead to
lysosomal membrane permeabilization and trigger the so-
called lysosomal apoptotic pathway [63, 64]. Furthermore,
it has been demonstrated that lysomotropic compounds
are able to increase lysosomal pH and as a consequence
decrease enzyme activity and proposed to impair lyso-
somal function [65]. Similar, a recent study has found that
lysosomal pH increase with Verteporfin induced cell tox-
icity in malignant hepatocellular cells only [66].
Today, two drugs approved for IPF treatment (Ninteda-
nib and Pirfenidone) are able to slow down disease progres-
sion, but adverse effects are common and no improvement
can be achieved in most patients. New therapeutic treat-
ments and treatment combinations are thus urgently
needed to not only stop, but also to reverse fibrosis. AZT is
a well tolerated macrolide antibiotic with tolerable side ef-
fects and could be a potential new additional therapeutic
drug for IPF, but additional in vivo studies and prospective
clinical trials are needed to confirm its anti-fibrotic effects.
Conclusions
Our study shows that AZT has a greater anti-fibrotic ef-
fect regarding collagen and fibronectin secretion as well
as myofibroblast differentiation in IPF compared to con-
trols. Moreover, AZT has enhanced pro-apoptotic effects
on IPF fibroblasts. The impaired lysosomal function in
IPF fibroblasts after additional AZT treatment could ex-
plain cell damage with higher apoptosis levels in IPF fi-
broblasts. Our findings may stimulate new treatment
strategies for IPF patients, but need to be tested in con-
trolled clinical trials.
(See figure on previous page.)
Fig. 6 Azithromycin affects vacuolar ATPases and impairs the lysosomal pH. a Microarray analysis revealed the engagement of various vacuolar
ATPases. Particularly ATP6V1B2 gene expression was increased, which suggests the involvement of lysosomal acidification. b ATP6V1B2 gene
expression was significantly upregulated in control and IPF fibroblasts after additional AZT (T + A) compared to TGF-β alone
(*p-value ≤0.0, n = 4), although no difference was observed for ATP6V1B2 between controls and IPF-FB. c ATP6V0D2 gene expression was
significantly higher upregulated in controls after additional AZT (T + A) compared to IPF (*p-value ≤0.05, n = 4). d A representative histogram of
control and IPF treated fibroblasts measured by flow cytometry is shown. Notably, a shift of the lysosomal pH represented by the FITC signal is
seen after AZT treatment in both control and IPF fibroblasts and slightly stronger in the IPF fibroblasts. Combined data (n = 4, each) from
independent experiments are shown in e AZT in the presence or absence of TGF-β induced a significant increase of the lysosomal pH in both
control (n = 4, ****p-value ≤0.0001) and IPF fibroblasts (n = 4, ****p-value ≤0.0001). Lysosomal pH was significantly different between control and
IPF fibroblasts after additional AZT (*p-value ≤0.05). All experiments were performed in three independent settings. One-way ANOVA followed by
Tukey’s post test was used for statistical analysis
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Supplementary information accompanies this paper at https://doi.org/10.
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Additional file 1. Figure S1. Azithromycin reduces gene expression of
fibronectin and αSMA in IPF and control fibroblasts. Figure S2. SMAD
phosporylation is not influenced by Azithromycin in IPF and control
fibroblasts. Figure S3. Azithromycin does not alter protein expression of
ATP6V1B2 in IPF and control fibroblasts.
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